Acquired mutations are pervasive across normal tissues. However, understanding of the processes that drive transformation of certain clones to cancer is limited. Here we study this phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy-related myeloid neoplasms (tMNs). We find that mutations are selected differentially based on exposures. Mutations in ASXL1 are enriched in current or former smokers, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2). Sequential sampling provides definitive evidence that DNA damage response clones outcompete other clones when exposed to certain therapies. Among cases in which CH was previously detected, the CH mutation was present at tMN diagnosis. We identify the molecular characteristics of CH that increase risk of tMN. The increasing implementation of clinical sequencing at diagnosis provides an opportunity to identify patients at risk of tMN for prevention strategies.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Translational Medicine Communications Open Access 01 October 2023
Scientific Reports Open Access 24 July 2023
Germline de novo mutations in families with Mendelian cancer syndromes caused by defects in DNA repair
Nature Communications Open Access 19 June 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The minimal clinical and mutational data necessary to replicate the findings in the article, except those shown in Extended Data Fig. 5 and Supplementary Fig. 12, are publicly available on GitHub: https://github.com/papaemmelab/bolton_NG_CH. Data for the excepted figures (individual drug names and start and stop dates, and combinations of mutations at tMN diagnosis, respectively) cannot be made public to preserve patient anonymity. Raw sequencing data cannot be publicly deposited for legal and privacy reasons, as sequencing was performed for clinical purposes. Mutation calls are available on cBioPortal: http://www.cbioportal.org/study/summary?id=msk_ch_2020
The codes to replicate the findings in the article, except those shown in Extended Data Fig. 5 and Supplementary Fig. 12, are publicly available on GitHub: https://github.com/papaemmelab/bolton_NG_CH. The codes used to generate the excepted figures are not included because the data cannot be shared (see above).
Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8, 1–12 (1954).
Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795–806 (2012).
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260–264 (2016).
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018).
Martincorena, I., Jones, P. H. & Campbell, P. J. Constrained positive selection on cancer mutations in normal skin. Proc. Natl Acad. Sci. USA 113, E1128–E1129 (2016).
Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
Yokoyama, A. et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565, 312–317 (2019).
Suda, K. et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 24, 1777–1789 (2018).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10, 1239–1245 (2015).
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
Fernandez-Antoran, D. et al. Outcompeting p53-mutant cells in the normal esophagus by redox manipulation. Cell Stem Cell 25, e6 (2019).
Hsu, J. I. et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23, 700–713.e6 (2018).
Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552–555 (2015).
Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400–404 (2018).
Desai, P. et al. Somatic mutations predict acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015–1023 (2018).
Morton, L. M. et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121, 2996–3004 (2013).
McNerney, M. E., Godley, L. A. & Le Beau, M. M. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat. Rev. Cancer 17, 513–527 (2017).
Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382.e4 (2017).
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).
Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).
Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
Grinfeld, J. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N. Engl. J. Med. 379, 1416–1430 (2018).
Bick, A. G. et al. Inherited causes of clonal hematopoiesis of indeterminate potential in TOPMed whole genomes. Preprint at bioRxiv https://doi.org/10.1101/782748 (2019).
Lindsley, R. C. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125, 1367–1376 (2015).
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Cancer Genome Atlas Research Network et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Gillis, N. K. et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 18, 112–121 (2017).
Takahashi, K. Germline polymorphisms and the risk of therapy-related myeloid neoplasms. Best Pract. Res. Clin. Haematol. 32, 24–30 (2019).
Gibson, C. J. et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 1598–1605 (2017).
Young, A. L., Tong, R. S., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis and risk of acute myeloid leukemia. Haematologica 104, 2410–2417 (2019).
Fianchi, L. et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am. J. Hematol. 90, E80–E85 (2015).
Choudhury, P. P. et al. iCARE: an R package to build, validate and apply absolute risk models. PLoS ONE 15, e0228198 (2020).
Maas, P. et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2, 1295–1302 (2016).
Candido Dos Reis, F. J. et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. 19, 58 (2017).
Meng, A., Wang, Y., Van Zant, G. & Zhou, D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 63, 5414–5419 (2003).
Hu, W. et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin. Cancer Res. 22, 2000–2008 (2016).
Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580–584 (2018).
Zhu, M. et al. Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. Cell 177, 608–621.e12 (2019).
Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863–864 (2011).
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
Papaemmanuil, E. et al. Identification of novel somatic mutations in SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts and other common cancers. Eur. J. Cancer 47, 7 (2011).
Campo, E. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn, Vol. 2 (IARC, 2017).
Wolff, A. C. et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J. Clin. Oncol. 33, 340–348 (2015).
Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2017) (National Cancer Institute, DCCPS, Surveillance Research Program, 2018); www.seer.cancer.gov/popdata
This work was supported by the National Institutes of Health (grant no. K08 CA241318 to K.L.B., grant no. K12 CA120780 to C.C.C., grant no. P50 CA172012 to L.B., grant no. P50 CA172012 to J.F., grant no. UG1 HL069315 to V.M.K.), the American Society of Hematology (K.L.B. and E. Papaemmanuil), the EvansMDS Foundation (K.L.B.), the European Hematology Association (E. Papaemmanuil), Gabrielle’s Angels Foundation (E. Papaemmanuil), the V Foundation (E. Papaemmanuil), the Geoffrey Beene Foundation (E. Papaemmanuil), the UNC Oncology Clinical Translational Research Training Program (C.C.C.), Cycle for Survival (V.M.K.), the Starr Cancer Consortium (to R.L.L., A.Z., M.F.B., R.N.P.) and the Cancer Colorectal Cancer Dream Team Translational Research Grant (grant no. SU2C-AACR-DT22-17 to L.A.D.). E. Papaemmanuil is a Josie Robertson Investigator. C.C.C. is a recipient of the Conquer Cancer Foundation Young Investigator Award and the Prostate Cancer Foundation Young Investigator Award. K.H.S. is a recipient of the Defense Early Investigator Research Award (grant no. W81XWH-18-1-0330), the Prostate Cancer Foundation Young Investigator Award and the Prostate Cancer Foundation Challenge Award. C.L., M.G.-C. and L.M.M. are supported by funds from the Intramural Research Program of the National Cancer Institute, National Institutes of Health. Work performed at Memorial Sloan Kettering Cancer Center was supported in part by the Cancer Center Support Grant (grant no. P30 CA008748). N.G.’s work was supported in part by the Tissue Core and Genomic Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center (grant no. P30 CA076292). The University of Cambridge has received salary support in respect of P.D.P.P. from the NHS in the East of England through the Clinical Academic Reserve.
The authors declare the following competing interests: K.L.B. has received research funding from GRAIL. C.C.C. has received honoraria from AbbVie, Loxo, H3 Biomedicine, Medscape, Octapharma and Pharmacyclics; has served as a consultant for AbbVie, Covance, Cowen & Co. and Dedham Group; and has received institutional research funding from AROG, Gilead, Loxo, H3 Biomedicine and Incyte. Z.S. has an immediate family member who holds consulting/advisory roles within the field of ophthalmology with Allergan, Adverum Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio and Spark Therapeutics. E.B. receives research funding from Celgene. D.G. is a consultant of MNM Diagnostics and has received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, Illumina and Kyowa Hakko Kirin. S.L. is an employee of GRAIL. M.E.R. holds an uncompensated advisory role with AstraZeneca, Daiichi-Sankyo, Merck and Pfizer and receives institutional research funding from AstraZeneca, AbbVie, Medivation and Pfizer. B.L.E. has received research funding from Celgene and Deerfield. T.D. is the Chief Medical Officer, ArcherDX, Inc. and receives salary from and holds an ownership stake in the company. K.T. receives consultancy fees from Symbio Pharmaceuticals. D.M.H. has consulted for Fount, Chugai, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer and Genentech/Roche; has equity in Fount; and has received research grants from Loxo, Bayer, Puma and AstraZeneca. J.B. is an employee of AstraZeneca; is on the Board of Directors of Foghorn and is a past board member of Varian Medical Systems, Bristol‐Myers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals; has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Eli Lilly, Seragon, Novartis and Northern Biologics; has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity Pharmaceuticals, ApoGen and Northern Biologics, as well as Tango and Venthera, for which he is a co‐founder; and has previously received honoraria or travel expenses from Roche, Novartis and Eli Lilly. M. Ladanyi serves on the advisory boards for AstraZeneca, Bristol Myers Squibb, Takeda, Bayer and Merck, and has received research support from Loxo Oncology and Helsinn Therapeutics. D.B.S. has served as a consultant for or received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina and Vivideon Therapeutics. M.F.B. is on the advisory board for Roche and receives research support from Illumina. M.S.T. receives research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics and Biosight; serves on the advisory boards of Daiichi-Sankyo, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze and Jazz Pharma; has received royalties from UpToDate; and has received research funding from Incyte, Kura Oncology and Celgene. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant for Merck (with the exception of travel and research support for clinical trials); is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University, some of which are associated with equity or royalty payments directly to Johns Hopkins and L.A.D.; and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his wife holds equity in Amgen. The terms of all of these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which include equity interest; receives research support from and has consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis; and has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. A.Z. received honoraria from Illumina. E. Papaemmanuil receives research funding from Celgene and is a cofounder in Isabl Technologies, a software analytics company for high-throughput clinical whole-genome and RNA-sequencing analyses. The remaining authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended Data Fig. 1 Distribution of cancer therapy received prior to blood collection for sequencing.
a, Frequency of patients receiving systemic therapy or external beam radiation therapy by primary tumor type. b, Frequency of patients receiving specific classes of systemic therapy by primary tumor type. c, Frequency of patients receiving top ten subclasses of cytotoxic therapy. Most patients (91%) who received at least one of these cytotoxic therapy classes received multiple classes.
Odds ratios (circle) and 95% confidence intervals for CH-PD in selected primary tumor types with at least 100 subjects compared to breast cancer (n = 3540) in a logistic regression model adjusted for age. * p < 0.05, ** p < 0.01, *** p < 0.001.
Genes mutated in at least 75 individuals and the top 12 primary tumor sites are shown.
Plots show changes in mutational frequencies in relation to cancer therapy exposure in 19 CH cases. Below each graph are listed treatments received prior to pre-tMN testing and the number of days between the end of treatment and the pre-tMN sample.
Extended Data Fig. 5 Differences in the fitness effect of CH mutations and the environment shape clonal dominance over an individual’s lifetime.
Conceptual graph illustrating how associations between specific exposures and CH mutations may shape clonal dominance over an individual’s lifetime. AML, acute myeloid leukemia; cyclophosph, cyclophosphamide; MDS, myelodysplastic syndrome.
About this article
Cite this article
Bolton, K.L., Ptashkin, R.N., Gao, T. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52, 1219–1226 (2020). https://doi.org/10.1038/s41588-020-00710-0
This article is cited by
Translational Medicine Communications (2023)
Blood Cancer Journal (2023)
Nature Communications (2023)
Scientific Reports (2023)